# HLA-DRα (h2): 293T Lysate: sc-117373



The Power to Question

#### **BACKGROUND**

Major histocompatibility complex (MHC) class II molecules destined for presentation to CD4+ helper T cells is determined by two key events. These events include the dissociation of class II-associated invariant chain peptides (CLIP) from an antigen binding groove in MHC II- $\alpha/\beta$  dimers through the activity of MHC molecules HLA-DM and -DO, and subsequent peptide antigen binding. Accumulating in endosomal/lysosomal compartments and on the surface of B cells, HLA-DM, -DO molecules regulate the dissociation of CLIP and the subsequent binding of exogenous peptides to HLA class II molecules (HLA-DR, -DQ and -DP) by sustaining a conformation that favors peptide exchange. RFLP analysis of HLA-DM genes from rheumatoid arthritis (RA) patients suggests that certain polymorphisms are genetic factors for RA susceptibility. HLA-B belongs to the HLA class I heavy chain paralogs. Class I molecules play a central role in the immune system by presenting peptides derived from the endoplasmic reticulum lumen. HLA-B and -C can form heterodimers consisting of a membrane-anchored heavy chain and a light chain (β-2-Microglobulin). Polymorphisms yield hundreds of HLA-B and -C alleles.

## **REFERENCES**

- Kropshofer, H., et al. 1998. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules. EMBO J. 17: 2971-2981.
- Siegmund, T., et al. 1999. HLA-DMA and HLA-DMB alleles in German patients with type 1 diabetes mellitus. Tissue Antigens 54: 291-294.
- 3. Arndt, S.O., et al. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J. 19: 1241-1251.
- 4. Brunet, A., et al. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-D0  $\beta$ . J. Biol. Chem. 275: 37062-37071.
- 5. Doebele, C.R., et al. 2000. Determination of the HLA-DM interaction site on HLA-DR molecules. Immunity 13: 517-527.
- Louis-Plence, P., et al. 2000. The down-regulation of HLA-DM gene expression in rheumatoid arthritis is not related to their promoter polymorphism.
  J. Immunol. 165: 4861-4869.
- Toussirot, E., et al. 2000. The association of HLA-DM genes with rheumatoid arthritis in Eastern France. Hum. Immunol. 61: 303-308.

#### CHROMOSOMAL LOCATION

Genetic locus: HLA-DRA (human) mapping to 6p21.32.

### **PRODUCT**

HLA-DR $\alpha$  (h2): 293T Lysate represents a lysate of human HLA-DR $\alpha$  transfected 293T cells and is provided as 100  $\mu$ g protein in 200  $\mu$ l SDS-PAGE buffer.

#### **STORAGE**

Store at -20° C. Repeated freezing and thawing should be minimized. Sample vial should be boiled once prior to use. Non-hazardous. No MSDS required.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

#### **APPLICATIONS**

HLA-DR $\alpha$  (h2): 293T Lysate is suitable as a Western Blotting positive control for human reactive HLA-DR $\alpha$  antibodies. Recommended use: 10-20  $\mu$ l per lane


Control 293T Lysate: sc-117752 is available as a Western Blotting negative control lysate derived from non-transfected 293T cells.


HLA-DR $\alpha$  (B-10): sc-55592 is recommended as a positive control antibody for Western Blot analysis of enhanced human HLA-DR $\alpha$  expression in HLA-DR $\alpha$  transfected 293T cells (starting dilution 1:100, dilution range 1:100-1:1,000).


#### **RECOMMENDED SUPPORT REAGENTS**

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-lgG $\kappa$  BP-HRP: sc-516102 or m-lgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>TM</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048.

#### **DATA**







HLA-DR $\alpha$  (G-7): sc-55593. Western blot analysis of HLA-DR $\alpha$  expression in non-transfected: sc-117752 (**A**) and human HLA-DR $\alpha$  transfected: sc-117373 (**B**) 293T whole cell Ivsates.

## **PROTOCOLS**

See our web site at www.scbt.com for detailed protocols and support products.

Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3801 Fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com